Scholarlink

Perseris® is the first subcutaneous long-acting injectable (LAI) risperidone product. As of July 2024, the marketing and sale of the medication have ceased. Per Indivior, the manufacturing of the medication was discontinued in May 2025. The final product has an expiration date of October 2026. After this date, the medication will no longer be available on the market in the United States. This chapter provides clinical pearls on how to appropriately prescribe and administer Perseris®.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Risperidone for Extended-Release Injectable Suspension (Perseris®): Second-Generation Antipsychotic Long-Acting Injectable

  • 章节

  • 发表日期：

    2025年

查看全文
  • Megan J. Ehret

摘要

Perseris® is the first subcutaneous long-acting injectable (LAI) risperidone product. As of July 2024, the marketing and sale of the medication have ceased. Per Indivior, the manufacturing of the medication was discontinued in May 2025. The final product has an expiration date of October 2026. After this date, the medication will no longer be available on the market in the United States. This chapter provides clinical pearls on how to appropriately prescribe and administer Perseris®.